Chapter 012

Anticonvulsants

Sean Flynn and M. Ali Babi

GENERAL REFERENCES

  1. Berg AT, Scheffer IE: New concepts in classification of the epilepsies: entering the 21st century, Epilepsia 52:1058–1062, 2011. PUBMED Abstract
  2. Brookes-Kayal AR, Bath KG, Berg AT, et al.: Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy, Epilepsia 54:44–60, 2013. PUBMED Abstract
  3. Cherubini E, Conti F: Generating diversity at GABAergic synapses, Trends Neurosci 24:155–162, 2001. PUBMED Abstract
  4. Hocker S, Wijdicks EF, Rabinstein AA: Refractory status epilepticus: new insights in presentation, treatment, and outcome, Neurol Res 35:163–168, 2013. PUBMED Abstract
  5. IOM (Institute of Medicine): Epilepsy across the spectrum: Promoting health and understanding, 1st ed., Washington, DC, 2012, The National Academies Press. PUBMED Abstract
  6. Mavrogiannis M, Ellis JS, Thomason JM, et al.: The management of drug-induced gingival overgrowth, J Clin Periodontol 33:434–439, 2006. PUBMED Abstract
  7. Noebels J: Pathway-driven discovery of epilepsy genes, Nat Neurosci 18:344–350, 2015. PUBMED Abstract
  8. Schousboe A, Madsen KK, Barker-Haliski ML, et al.: The GABA synapse as a target for antiepileptic drugs: a historical overview focused on GABA transporters, Neurochem Res 39:1980–1987, 2014. PUBMED Abstract
  9. Simonato M, Brooks-Kayal AR, Engel J, et al.: The challenge and promise of anti-epileptic therapy development in animal models, Lancet Neurol 13:949–960, 2014. PUBMED Abstract
  10. Stephen LJ, Brodie MJ: Antiepileptic drug monotherpay versus polytherapy: pursuing seizure freedom and tolerability in adults, Curr Opin Neurol 25:164–172, 2012. PUBMED Abstract